Cetera Advisor Networks LLC Incyte Corp Transaction History

Cetera Advisor Networks LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$52.16 - $64.19 $41,571 - $51,159	797 Added 19.41%	4,904 $307,000
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $23,627 - $26,965	409 Added 11.06%	4,107 $237,000
Q2 2023 Aug 09, 2023	SELL	$60.95 - $75.51 $198,757 - $246,238	-3,261 Reduced 46.86%	3,698 $230,000
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $76,410 - $93,578	1,088 Added 18.53%	6,959 $502,000
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $361,562 - $452,680	-5,382 Reduced 47.83%	5,871 $471,000
Q3 2022 Nov 10, 2022	SELL	$66.18 - $82.86 $202,907 - $254,048	-3,066 Reduced 21.41%	11,253 $750,000
Q2 2022 Aug 11, 2022	BUY	$66.18 - $83.18 $599,193 - $753,111	9,054 Added 171.97%	14,319 $1.09 Million
Q1 2022 May 12, 2022	BUY	$66.02 - $79.71 $23,899 - $28,855	362 Added 7.38%	5,265 $418,000
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $310,556 - $363,361	4,903 New	4,903 $360,000
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $51,977 - $67,020	-611 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$74.18 - $108.93 $45,323 - $66,556	611 New	611 $64,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisor Networks LLC with notifications on news.